within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H02C_AntiadrenalPreparations.H02CA02_Osilodrostat;

model Osilodrostat
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.98,
    Cl = 5.277777777777778e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.105,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0014333333333333331,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Osilodrostat</td></tr><tr><td>ATC code:</td><td>H02CA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>105</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Osilodrostat is an orally active, reversible inhibitor of the enzyme 11β-hydroxylase (CYP11B1), which is responsible for cortisol synthesis in the adrenal cortex. It is approved for the treatment of Cushing's syndrome, specifically for adults with endogenous Cushing's disease for whom pituitary surgery is not an option or has not been curative.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers, after single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H02CA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Osilodrostat;
